Clinical Trial Update: Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial of Garsorasib in KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Garsorasib

Snippet

Sponsor: Sun Yat-sen University | Conditions: Local Advanced or Metastatic NSCLC | Phase 2 | Status: NOT_YET_RECRUITING